Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 1/20 | 0.38 |
| ▸ | HTR2C | P28335 | 1/20 | 0.38 |
| ▸ | PTGDR2 | Q9Y5Y4 | 4/20 | 0.37 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.35 |
| ▸ | PTGDR | Q13258 | 2/20 | 0.34 |
| ▸ | PTGER2 | P43116 | 1/20 | 0.33 |
| ▸ | EGLN1 | Q9GZT9 | 2/20 | 0.32 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7675734 | 0.86 | MCL1 (0.41) | HTR2AHTR2CPTGDR2MCL1EGLN1 | |
| SCHEMBL7673368 | 0.85 | HTR2C (0.41) | HTR2AHTR2CPTGDR2MCL1PTGDR | |
| SCHEMBL6852208 | 0.81 | HTR2A (0.31) | HTR2AHTR2CPTGDR2MCL1 | |
| SCHEMBL7034581 | 0.79 | PTGDR2 (0.38) | HTR2AHTR2CPTGDR2MCL1PTGDR | |
| SCHEMBL7673244 | 0.79 | MAPT (0.30) | HTR2AHTR2CRIPK1 | |
| SCHEMBL7674690 | 0.78 | PTGDR (0.31) | PTGDR2PTGDR | |
| SCHEMBL6847452 | 0.77 | HTR2C (0.64) | HTR2AHTR2C | |
| Hydrochloric Acid SCHEMBL6493128 | 0.76 | HTR2C (0.62) | HTR2AHTR2C | |
| SCHEMBL7676778 | 0.76 | HTR2C (0.37) | HTR2AHTR2CPTGDR2MCL1EGLN1 | |
| SCHEMBL7672209 | 0.76 | HTR2C (0.36) | HTR2AHTR2CPTGDR2MCL1RIPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020198190-A1 | Tetracyclic azepinoindole compounds | PHARMACIA & UPJOHN COMPANY | 2002-12-26 | — | — | US | claimed |
| US-20020198190-A1 | Tetracyclic azepinoindole compounds | PHARMACIA & UPJOHN COMPANY | 2002-12-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020198190-A1 | Tetracyclic azepinoindole compounds | TPH1, AZI2, CYP1A2 | HTR2A 43/4885HTR2C 24/4885PTGDR2 314/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.